SLI
2.372,09
PKT
+4,77
PKT
+0,20
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 08.03.05 | UBS Overweight | Morgan Stanley | |
| 04.03.05 | Swisscom Neutral | Merrill Lynch | |
| 04.03.05 | Sika Neutral | Sarasin Research | |
| 04.03.05 | Swiss Life Kaufen | M.M. Warburg | |
| 04.03.05 | Richemont Buy | Sarasin Research | |
| 03.03.05 | Nestlé Kaufen | Helaba Trust | |
| 04.03.05 | Givaudan Underperform | Credit Suisse First Boston | |
| 04.03.05 | Holcim Accumulate | Helvea | |
| 02.03.05 | UBS Buy | Merrill Lynch | |
| 03.03.05 | Nestlé Buy | Helvea | |
| 03.03.05 | Givaudan Underperform | HypoVereinsbank | |
| 02.03.05 | Holcim Halten | Helaba Trust | |
| 03.03.05 | UBS Buy | SEB | |
| 02.03.05 | Nestlé Neutral | Sarasin Research | |
| 02.03.05 | Holcim Neutral | Sarasin Research | |
| 03.03.05 | Nestlé Übergewichten | Bankhaus Reuschel & Co | |
| 03.03.05 | Holcim Accumulate | Helvea | |
| 03.03.05 | Helvetia Baloise Outperform | Credit Suisse First Boston | |
| 01.03.05 | Nestlé Overweight | JP Morgan | |
| 02.03.05 | Holcim Outperform | Goldman Sachs | |
| 01.03.05 | Swiss Life Marketperformer | LB Rheinland-Pfalz | |
| 02.03.05 | Givaudan Neutral | Helvea | |
| 01.03.05 | UBS Kaufen | Helaba Trust | |
| 01.03.05 | Nestlé Sector Outperform | Vontobel | |
| 02.03.05 | Swiss Life Hold | Commerzbank | |
| 02.03.05 | Givaudan Neutral | Sarasin Research | |
| 01.03.05 | Swiss Life Buy | M.M. Warburg | |
| 01.03.05 | Swisscom Neutral | Helvea | |
| 01.03.05 | Roche Buy | Sarasin Research | |
| 28.02.05 | Nestlé Akkumulieren | Independent Research | |
| 01.03.05 | Swiss Life Outperform | HypoVereinsbank | |
| 25.02.05 | UBS Buy | Commerzbank | |
| 25.02.05 | Holcim Overweight | JP Morgan | |
| 25.02.05 | Nestlé In-Line | Goldman Sachs | |
| 25.02.05 | Holcim In-Line | Goldman Sachs | |
| 28.02.05 | Nestlé Buy | Helvea | |
| 28.02.05 | Nestlé Halten | Hamburger Sparkasse | |
| 28.02.05 | Nestlé Buy | Sal. Oppenheim | |
| 25.02.05 | Givaudan Neutral | Sarasin Research | |
| 24.02.05 | Novartis Overweight | Lehman Brothers |